Provided are metabolites of palonosetron that can be used in treating animals, particularly humans, of the formula (I): or a pharmaceutically acceptable salt or prodrug thereof; wherein R
1
and R
4
independently can be H, hydroxyl, or carbonyl; and wherein R
3
can be Formule (II) or Formule (III).